Cerity Partners LLC Acquires 89,089 Shares of GSK plc (NYSE:GSK)

Cerity Partners LLC boosted its position in shares of GSK plc (NYSE:GSK) by 305.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 118,233 shares of the pharmaceutical company’s stock after buying an additional 89,089 shares during the quarter. Cerity Partners LLC’s holdings in GSK were worth $4,383,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FinTrust Capital Advisors LLC raised its holdings in GSK by 6.9% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 4,346 shares of the pharmaceutical company’s stock valued at $158,000 after buying an additional 281 shares during the last quarter. UMB Bank n.a. raised its holdings in GSK by 4.8% during the 3rd quarter. UMB Bank n.a. now owns 6,462 shares of the pharmaceutical company’s stock valued at $234,000 after buying an additional 297 shares during the last quarter. Fiduciary Group LLC raised its holdings in GSK by 3.3% during the 1st quarter. Fiduciary Group LLC now owns 9,367 shares of the pharmaceutical company’s stock valued at $342,000 after buying an additional 300 shares during the last quarter. KCS Wealth Advisory raised its holdings in GSK by 1.5% during the 3rd quarter. KCS Wealth Advisory now owns 21,391 shares of the pharmaceutical company’s stock valued at $775,000 after buying an additional 314 shares during the last quarter. Finally, BSW Wealth Partners raised its holdings in GSK by 5.2% during the 1st quarter. BSW Wealth Partners now owns 6,345 shares of the pharmaceutical company’s stock valued at $226,000 after buying an additional 316 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GSK. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Morgan Stanley began coverage on shares of GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

GSK Stock Down 1.4 %

Shares of GSK stock opened at $39.95 on Wednesday. The company’s fifty day simple moving average is $42.04 and its two-hundred day simple moving average is $38.76. The company has a market cap of $82.78 billion, a P/E ratio of 13.27, a PEG ratio of 1.86 and a beta of 0.64. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 1.19. GSK plc has a 12-month low of $33.33 and a 12-month high of $43.84.

GSK (NYSE:GSK) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The business had revenue of $10 billion during the quarter, compared to analysts’ expectations of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. Research analysts anticipate that GSK plc will post 4.03 EPS for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were given a $0.3564 dividend. The ex-dividend date of this dividend was Thursday, February 22nd. This is an increase from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.57%. GSK’s dividend payout ratio is currently 52.82%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.